These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38307808)
21. Novel therapies for unresectable and metastatic melanoma. Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943 [No Abstract] [Full Text] [Related]
22. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. Jespersen H; Bjursten S; Ny L; Levin M Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264 [No Abstract] [Full Text] [Related]
23. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. Li T; Jia DD; Teng LS Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356 [TBL] [Abstract][Full Text] [Related]
24. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma. Stauner CT; Drexler K; Berneburg M; Haferkamp S J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577 [No Abstract] [Full Text] [Related]
25. Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature. Song JC; Ding XL; Sun XH; Safi M; Tian J Medicine (Baltimore); 2017 Dec; 96(50):e9278. PubMed ID: 29390382 [TBL] [Abstract][Full Text] [Related]
26. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Shen L; Qi H; Chen S; Cao F; Xie L; Wu Y; Ma W; Song Z; Yuan H; Zhang T; Li D; Wen X; Chen Q; Li W; Zhang X; Fan W Cancer Immunol Immunother; 2020 Sep; 69(9):1713-1724. PubMed ID: 32333081 [TBL] [Abstract][Full Text] [Related]
27. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271 [TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576 [TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience. Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148 [TBL] [Abstract][Full Text] [Related]
30. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia. Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722 [No Abstract] [Full Text] [Related]
31. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465 [TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768 [TBL] [Abstract][Full Text] [Related]